Hannah E. Bergom

This study uses proteomic profiling of extracellular vesicles to distinguish prostate cancer subtypes and identify subtype-specific biomarkers.

This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

This paper introduces Local Leveling, a method to reduce bias in RNA-seq data, improving gene-gene relationship accuracy and statistical test results.